🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Sending warm wishes for a season brimming with love, laughter, and the joy of shared moments. Happy holidays to you and yours! #HappyHolidays #Excision

Wishing everyone a Happy New Year filled with joy, success, and exciting breakthroughs! From all of us at the Excision, may the coming year be one of prosperity and remarkable achievements. Here's to a fantastic journey ahead! #HappyNewYear #Excision

Excited to announce CEO, Daniel Dornbusch's panel on disruptive therapies at #BiotechShowcase2024 during #JPM2024 on Jan 9th, 8 a.m. PT. Thanks to Sara Jane Demy and Demy-Colton team for hosting!

Excision's CEO, Daniel Dornbusch, was delighted to attend this year's #JPM2024 and joined a panel at #BiotechShowcase. It was great meeting Lee Landenberger, BioWorld reporter. Read his recent article that highlights Excision. Read the article here: loom.ly/9-mncfo

Excision recently sat down with Victoria Johnson from AJMC to discuss our groundbreaking work in the field of CRSIPR and how we seek to suppress #HIV replication using #CRISPR gene editing. Read the article here: loom.ly/qMYoiDs #ExcisionBio HIVResearch

Our team is off to the 7th Annual Cell & Gene Therapy Innovation Leaders Summit 2024 in Barcelona, Spain! We're excited to connect with fellow industry leaders and share how Excision is working towards using #CRISPR technology to combat #HIV. #ExcisionBio #InnovationLeaders

Check out a recent article from Shawna Williams at @Biospace that highlights Excision's work and how we are setting the foundation for advancements of Excision’s pipeline. Read the article here: loom.ly/KfYZ4kQ

Attending the Oppenheimer 34th Annual Healthcare Life Sciences Conference? Excision will be presenting tomorrow, Tuesday, February 13th at 10:00am ET #ExcisionBio #HIV #LifeSciences #Oppenheimer2024

Thank you to Tim Murphy for his recent article highlighting Excision's work in using #CRISPR to combat #HIV. Read his article here: #ExcisionBio #SickleCell #CellGene #GeneEditing

Excision Biotherapeutics is proud to showcase our groundbreaking research at #ASGCT2024! Join us tomorrow, May 9th, as our talented team presents their cutting-edge data. Learn more at: loom.ly/aLsEjFo #ExcisionBio #ASGCT #GeneTherapy

Mark your calendars for tomorrow, May 10th! Excision Biotherapeutics is gearing up to present our latest advancements in gene editing at #ASGCT2024. Don't miss out on the opportunity to explore the forefront of biotechnology. Visit: loom.ly/aLsEjFo #ExcisionBio #ASGCT

TODAY | Join Dr. Rachel Presti for an update on Excision Biotherapeutics’ HIV-1 clinical trial at #ASGCT2024! Discover the transformative potential of our gene editing technologies firsthand. Learn more: loom.ly/aLsEjFo #ExcisionBio #ASGCT #GeneEditing

Today, Excision BioTherapeutics announced data from our Phase 1/2 Trial of EBT-101 in HIV and In Vivo Efficacy data in Herpes Virus and Hepatitis B. Read our press release: loom.ly/YxPaq_8 #Excision #Excisionbio

Celebrating a successful showcase at #ASGCT2024, Excision Biotherapeutics is proud to have shared our groundbreaking research at the event. We pushed the boundaries of gene therapy, leaving a lasting impact. #Excision #ExcisionBio

We're excited to share that Excision BioTherapeutics has been mentioned in a recent article highlighting our Phase 1/2 trial of EBT-101 in HIV and promising preclinical results for herpes and hepatitis B. loom.ly/L8u-X08

We're honored to have been awarded one of the 'Fierce 15' Biotech Companies of 2024 by Fierce Biotech. Our unique use of CRISPR/Cas gene editing has recently achieved in vivo proof-of-concept in combating Herpes Virus and Hepatitis B. loom.ly/1IfiuqE #Excision

Today, Excision announced a new publication in Molecular Therapy Methods & Clinical Development on EBT-104 for HSV-1 keratitis treatment. 📍Read the full publication: excision.bio/news/press-rel… #ExcisionBio #MolecularTherapy #HSV #CRISPR #GeneEditing

Join us today at 2:30 pm CDT as Dr. Ryo Takeuchi, Senior Director of Genome Editing at Excision, presents on 'Development of Multiplex Gene Editing Therapy for Chronic Hepatitis B' at the 2024 International HBV Meeting. Learn more: loom.ly/1IfiuqE

Excision presented data on EBT-107 at the 2024 International HBV Meeting, highlighting its potential to increase Hepatitis B cure rates. Learn more: loom.ly/1IfiuqE

Dr. Ryo Takeuchi, Sr. Director, Genome Editing at Excision, will present on leveraging EBT-101 preclinical and clinical insights for new in vivo multiplex editing programs. Learn more: loom.ly/1IfiuqE